| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marina Han, Aleen Saxton, Heather Currey, Sarah M Waldherr, Nicole F Liachko, Brian C Kraeme. Transgenic Dendra2::tau expression allows in vivo monitoring of tau proteostasis in C. elegans. Disease models & mechanisms. 2024-03-12. PMID:38469687. |
protein homeostasis is perturbed in aging-related neurodegenerative diseases called tauopathies, which are pathologically characterized by aggregation of the microtubule-associated protein tau. |
2024-03-12 |
2024-03-14 |
caenorhabditis_elegans |
| Cassis Varlow, Chester A Mathis, Neil Vasde. In vitro evaluation of [ Nuclear medicine and biology. vol 130-131. 2024-03-08. PMID:38458074. |
in vitro evaluation of [ alzheimer's disease (ad) and non-ad tauopathies such as chronic traumatic encephalopathy (cte), progressive supranuclear palsy (psp), and corticobasal degeneration (cbd) are characterized by the abnormal aggregation of three-repeat (3r) and/or four-repeat (4r) tau isoforms. |
2024-03-08 |
2024-03-11 |
human |
| Anuradha Venkatramani, Anvesh Ashtam, Dulal Pand. EB1 Increases the Dynamics of Tau Droplets and Inhibits Tau Aggregation: Implications in Tauopathies. ACS chemical neuroscience. 2024-03-06. PMID:38445984. |
eb1 increases the dynamics of tau droplets and inhibits tau aggregation: implications in tauopathies. |
2024-03-06 |
2024-03-08 |
Not clear |
| Wanbing Zhao, Kaien Liu, Yun Fan, Qinyue Zhao, Youqi Tao, Mengwei Zhang, Linhua Gan, Wenbo Yu, Bo Sun, Dan Li, Cong Liu, Jian Wan. Cryo-EM structures reveal variant Tau amyloid fibrils between the rTg4510 mouse model and sporadic human tauopathies. Cell discovery. vol 10. issue 1. 2024-03-06. PMID:38448404. |
cryo-em structures reveal variant tau amyloid fibrils between the rtg4510 mouse model and sporadic human tauopathies. |
2024-03-06 |
2024-03-09 |
mouse |
| YouJin Lee, Eric M Morro. Quantitative Measurement of Tau Aggregation in Genetically Modified Rats with Neurodegeneration. Methods in molecular biology (Clifton, N.J.). vol 2761. 2024-03-01. PMID:38427245. |
also, certain rat models can represent deposition of tau, which is one of the key pathological features of alzheimer's diseases and tauopathies. |
2024-03-01 |
2024-03-03 |
mouse |
| Abhay Kumar Singh, Karthikeyan Selvarasu, Siva Sundara Kumar Durairaja. Isolation and Detection of Pathological Tau Species in a Tauopathy Mouse Model. Methods in molecular biology (Clifton, N.J.). vol 2761. 2024-03-01. PMID:38427247. |
tau protein in alzheimer's disease (ad) and tauopathies becomes insoluble due to hyperphosphorylation, conformational alterations, and aggregation. |
2024-03-01 |
2024-03-03 |
mouse |
| Abhay Kumar Singh, Karthikeyan Selvarasu, Siva Sundara Kumar Durairaja. Isolation and Detection of Pathological Tau Species in a Tauopathy Mouse Model. Methods in molecular biology (Clifton, N.J.). vol 2761. 2024-03-01. PMID:38427247. |
additionally, the study employs immunohistochemistry to visualize and quantify the pathological tau species in the brain tissue of transgenic mice, aiming to identify and analyze pathological tau species such as hyperphosphorylated tau to further our understanding of tauopathies such as alzheimer's disease. |
2024-03-01 |
2024-03-03 |
mouse |
| Philippe Verwaerde, Cécilia Estrella, Stéphane Burlet, Mathieu Barrier, Andrée-Anne Marotte, Gilbert Clinck. First-In-Human Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of AZP2006, A Synthetic Compound for the Treatment of Alzheimer's Disease and Related Diseases. Journal of Alzheimer's disease : JAD. 2024-03-01. PMID:38427472. |
azp2006, a synthetic compound, targets tauopathies by stabilizing pgrn levels and reducing tau aggregation and neuroinflammation. |
2024-03-01 |
2024-03-04 |
Not clear |
| Einar M Sigurdsso. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies. Journal of Alzheimer's disease : JAD. 2024-03-01. PMID:38427486. |
tau immunotherapies for alzheimer's disease and related tauopathies: status of trials and insights from preclinical studies. |
2024-03-01 |
2024-03-04 |
Not clear |
| Einar M Sigurdsso. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies. Journal of Alzheimer's disease : JAD. 2024-03-01. PMID:38427486. |
the tau protein undergoes pathological changes in alzheimer's disease and other tauopathies that eventually lead to functional impairments. |
2024-03-01 |
2024-03-04 |
Not clear |
| Bryan Alava, Gabriela Hery, Silvana Sidhom, Miguel Gutierrez-Monreal, Stefan Prokop, Karyn A Esser, Jose Abisambr. Targeted brain-specific tauopathy compromises peripheral skeletal muscle integrity and function. Aging brain. vol 5. 2024-02-29. PMID:38419621. |
tauopathies are neurodegenerative disorders in which the pathological intracellular aggregation of the protein tau causes cognitive deficits. |
2024-02-29 |
2024-03-02 |
mouse |
| Liara Rizzi, Lea T Grinber. Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting. Acta neuropathologica communications. vol 12. issue 1. 2024-02-28. PMID:38419122. |
exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in alzheimer's disease: implications for biomarker development and therapeutic targeting. |
2024-02-28 |
2024-03-02 |
Not clear |
| Liara Rizzi, Lea T Grinber. Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting. Acta neuropathologica communications. vol 12. issue 1. 2024-02-28. PMID:38419122. |
furthermore, these caspase-cleaved tau species are nearly absent in 4-repeat tauopathies. |
2024-02-28 |
2024-03-02 |
Not clear |
| Liara Rizzi, Lea T Grinber. Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting. Acta neuropathologica communications. vol 12. issue 1. 2024-02-28. PMID:38419122. |
in this review, we will discuss the significance of caspase-cleaved tau in the development of tauopathies, specifically emphasizing its role in ad. |
2024-02-28 |
2024-03-02 |
Not clear |
| Liara Rizzi, Lea T Grinber. Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting. Acta neuropathologica communications. vol 12. issue 1. 2024-02-28. PMID:38419122. |
developing specific and sensitive assays for caspase-cleaved tau in biofluids holds promise for improving the diagnosis and monitoring of tauopathies, providing valuable insights into disease progression and treatment efficacy. |
2024-02-28 |
2024-03-02 |
Not clear |
| Nadia El Mammeri, Aurelio J Dregni, Pu Duan, Mei Hon. Structures of AT8 and PHF1 phosphomimetic tau: Insights into the posttranslational modification code of tau aggregation. Proceedings of the National Academy of Sciences of the United States of America. vol 121. issue 10. 2024-02-28. PMID:38408247. |
in these tauopathies, tau is hyperphosphorylated, suggesting that this posttranslational modification (ptm) may induce tau aggregation. |
2024-02-28 |
2024-03-01 |
Not clear |
| Koping Chang, Alexander Barrett, Khoa Pham, Juan C Troncos. Lateral geniculate body is spared of tau pathology in Pick disease. Journal of neuropathology and experimental neurology. 2024-02-27. PMID:38412343. |
by contrast, the lgb does consistently harbor tau lesions in other tauopathies including progressive supranuclear palsy, corticobasal degeneration, and ad. |
2024-02-27 |
2024-03-01 |
Not clear |
| Nuo Jia, Dhasarathan Ganesan, Hongyuan Guan, Yu Young Jeong, Sinsuk Han, Marialaina Nissenbaum, Alexander W Kusnecov, Qian Ca. Mitochondrial bioenergetics stimulates autophagy for pathological tau clearance in tauopathy neurons. bioRxiv : the preprint server for biology. 2024-02-26. PMID:38405759. |
hyperphosphorylation and aggregation of microtubule-associated tau is a pathogenic hallmark of tauopathies and a defining feature of alzheimer's disease (ad). |
2024-02-26 |
2024-02-28 |
mouse |
| Nuo Jia, Dhasarathan Ganesan, Hongyuan Guan, Yu Young Jeong, Sinsuk Han, Marialaina Nissenbaum, Alexander W Kusnecov, Qian Ca. Mitochondrial bioenergetics stimulates autophagy for pathological tau clearance in tauopathy neurons. bioRxiv : the preprint server for biology. 2024-02-26. PMID:38405759. |
taken together, our study sheds light on a pivotal role of bioenergetic dysfunction in tauopathy-linked autophagy defects and suggests a new therapeutic strategy to prevent toxic tau buildup in ad and other tauopathies. |
2024-02-26 |
2024-02-28 |
mouse |
| Bang Wang, Xiaoshu Pan, I-Ting Teng, Xiaowei Li, Firas Kobeissy, Zo-Yu Wu, Jiepei Zhu, Guangzheng Cai, He Yan, Xin Yan, Mingwei Liang, Fahong Yu, Jianrong Lu, Zunyi Yang, Elisa Biondi, William Haskins, Y Charles Cao, Steven A Benner, Weihong Tan, Kevin Wan. Functional Selection of Tau Oligomerization-Inhibiting Aptamers. Angewandte Chemie (International ed. in English). 2024-02-26. PMID:38407551. |
pathological hyperphosphorylation and aggregation of microtubule-associated tau protein contribute to alzheimer's disease (ad) and other related tauopathies. |
2024-02-26 |
2024-02-28 |
Not clear |